SINGLE-AF: DOACs cut composite adverse events ~69% in intermediate-risk atrial fibrillation (Cardiology)

Sciencedesk view

SINGLE-AF: DOACs cut composite adverse events ~69% in intermediate-risk atrial fibrillation (Cardiology)

The SINGLE-AF trial, led by Boyoung Joung of Yonsei University, was presented Aug. 28 in a Hot Line session at ESC Congress 2026 and published simultaneously in…

READ THE DAY'S DIGEST →

Sports/Healthdesk view

STAREE large RCT: Atorvastatin primary prevention in ≥70s without known CVD cuts major CV events ~30% (Public health)

The STAREE double-blind placebo-controlled trial led by Zoungas (Monash University) was presented in an ESC Congress 2026 Hot Line on 2026-08-29 and published s…

READ THE DAY'S DIGEST →